Skip to Content
CancersCancers
  • Review
  • Open Access

31 March 2025

15 Pages

The Current State of Bispecific Antibodies and T-Cell Directed Therapy in NHL

,
and
1
City of Hope Comprehensive Cancer Center, Department of Hematology and Hematopoietic Cell Transplantation, Division of Lymphoma, Duarte, CA 91010, USA
2
Rogel Comprehensive Cancer Center, University of Michigan-Ann Arbor, Ann Arbor, MI 48109, USA
*
Author to whom correspondence should be addressed.

Simple Summary

This is a review article detailing available evidence on the use of CAR-T cell therapy and bispecific antibodies (BsAbs) in non-Hodgkin’s lymphoma—specifically diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The review hopes to detail where CAR T-cell therapy and BsAbs fit in our current treatment paradigm, as well as foreshadow what is to come in the near future.

Abstract

Relapsed/refractory non-Hodgkin lymphoma (r/r/NHL) is an aggressive disease with overall poor response rates to chemo-immunotherapy and autologous stem-cell transplant, especially in patients with diffuse large B-cell lymphoma. Major improvements in this disease space have come through the incorporation of novel immune therapies, including CD19/CD20 directed CAR-T cells and bispecific antibodies. These exciting new therapies continue to change the landscape of treatment for r/r NHL and have been incorporated in earlier lines of therapy with demonstrated efficacy and patient safety. In this review, the role of these treatments in the management of relapsed/refractory NHL is discussed in detail along with future directions of research.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.